Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Topiramate for the Treatment of Methamphetamine Dependence - 1

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: June 27, 2006
Last updated: December 21, 2007
Last verified: December 2007
The purpose of this study is to assess the efficacy and safety of topiramate as compared to placebo in reducing methamphetamine use in subjects with methamphetamine dependence.

Condition Intervention Phase
Drug: Topiramate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2, Double-Blind, Placebo-Controlled Trial of Topiramate for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Abstinence [ Time Frame: weekly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety [ Time Frame: weekly ] [ Designated as safety issue: Yes ]
  • Withdrawal [ Time Frame: weekly ] [ Designated as safety issue: No ]
  • Severity of methamphetamine dependence [ Time Frame: weekly ] [ Designated as safety issue: No ]
  • Methamphetamine Craving [ Time Frame: weekly ] [ Designated as safety issue: No ]

Estimated Enrollment: 140
Study Start Date: April 2006
Study Completion Date: December 2007
Estimated Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Topiramate
100 mg


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Treatment seeking individuals as the time of the study
  • Must be able to proved written informed consent
  • Must have a body mass index greater than 18 kg/m(2)
  • Must meet DSM-IV criteria for methamphetamine dependence
  • Must currently be using methamphetamine as confirmed by a positive urine test over the past 14 days
  • If female of child bearing potential, must agree to use birth control

Exclusion Criteria:

  • Please contact the site for more information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00345371

United States, California
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
South Bay Treatment Center
San Diego, California, United States, 92105
Torrance Site
Torrance, California, United States, 90502
United States, Hawaii
John A. Burns School of Medicine
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
University of Missouri - Kansas City
Kansas City, Missouri, United States, 64108
United States, Utah
Salt Lake City VA Medical Center
Salt Lake City, Utah, United States, 84148
United States, Virginia
Charlottesville, Virginia, United States, 22911
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Bankole Johnson VA Office of Research and Development
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Liza Gorgon, National Institute on Drug Abuse Identifier: NCT00345371     History of Changes
Obsolete Identifiers: NCT00431652
Other Study ID Numbers: NIDA-CSP-1025-1 
Study First Received: June 27, 2006
Last Updated: December 21, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors
Neuroprotective Agents
Protective Agents
Anti-Obesity Agents processed this record on December 08, 2016